Cargando…
Three-Dimensional Amide Proton Transfer-Weighted Imaging for Differentiating between Glioblastoma, IDH-Wildtype and Primary Central Nervous System Lymphoma
SIMPLE SUMMARY: Although primary central nervous system lymphoma (PCNSL) is sometimes indistinguishable from glioblastoma, isocitrate dehydrogenase (IDH)-wildtype, the role of operation on them is very different; therefore, accurate preoperative diagnosis is crucial. In this study, we evaluated whet...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913574/ https://www.ncbi.nlm.nih.gov/pubmed/36765909 http://dx.doi.org/10.3390/cancers15030952 |
_version_ | 1784885460534820864 |
---|---|
author | Ohba, Shigeo Murayama, Kazuhiro Teranishi, Takao Kumon, Masanobu Nakae, Shunsuke Yui, Masao Yamamoto, Kaori Yamada, Seiji Abe, Masato Hasegawa, Mitsuhiro Hirose, Yuichi |
author_facet | Ohba, Shigeo Murayama, Kazuhiro Teranishi, Takao Kumon, Masanobu Nakae, Shunsuke Yui, Masao Yamamoto, Kaori Yamada, Seiji Abe, Masato Hasegawa, Mitsuhiro Hirose, Yuichi |
author_sort | Ohba, Shigeo |
collection | PubMed |
description | SIMPLE SUMMARY: Although primary central nervous system lymphoma (PCNSL) is sometimes indistinguishable from glioblastoma, isocitrate dehydrogenase (IDH)-wildtype, the role of operation on them is very different; therefore, accurate preoperative diagnosis is crucial. In this study, we evaluated whether amide proton transfer-weighted (APTw) imaging was useful to distinguish PCNSL from glioblastoma, IDH-wildtype. The mean APTw signal value did not significantly differ between them; however, the percentile values from the 1st percentile to the 20th percentile APTw signals and the width(1–100) APTw signals between the two diseases were significantly different. The area under the curve, sensitivity, and specificity were 0.796, 64.3%, and 88.9%, respectively, using the width(1–100) APTw signal values. APTw imaging was useful to differentiate between PCNSL and glioblastoma, IDH-wildtype. Performing APTw imaging is recommended in cases in which PCNSL is one of the differential diagnoses. ABSTRACT: Distinguishing primary central nervous system lymphoma (PCNSL) from glioblastoma, isocitrate dehydrogenase (IDH)-wildtype is sometimes hard. Because the role of operation on them varies, accurate preoperative diagnosis is crucial. In this study, we evaluated whether a specific kind of chemical exchange saturation transfer imaging, i.e., amide proton transfer-weighted (APTw) imaging, was useful to distinguish PCNSL from glioblastoma, IDH-wildtype. A total of 14 PCNSL and 27 glioblastoma, IDH-wildtype cases were evaluated. There was no significant difference in the mean APTw signal values between the two groups. However, the percentile values from the 1st percentile to the 20th percentile APTw signals and the width(1–100) APTw signals significantly differed. The highest area under the curve was 0.796, which was obtained from the width(1–100) APTw signal values. The sensitivity and specificity values were 64.3% and 88.9%, respectively. APTw imaging was useful to distinguish PCNSL from glioblastoma, IDH-wildtype. To avoid unnecessary aggressive surgical resection, APTw imaging is recommended for cases in which PCNSL is one of the differential diagnoses. |
format | Online Article Text |
id | pubmed-9913574 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99135742023-02-11 Three-Dimensional Amide Proton Transfer-Weighted Imaging for Differentiating between Glioblastoma, IDH-Wildtype and Primary Central Nervous System Lymphoma Ohba, Shigeo Murayama, Kazuhiro Teranishi, Takao Kumon, Masanobu Nakae, Shunsuke Yui, Masao Yamamoto, Kaori Yamada, Seiji Abe, Masato Hasegawa, Mitsuhiro Hirose, Yuichi Cancers (Basel) Article SIMPLE SUMMARY: Although primary central nervous system lymphoma (PCNSL) is sometimes indistinguishable from glioblastoma, isocitrate dehydrogenase (IDH)-wildtype, the role of operation on them is very different; therefore, accurate preoperative diagnosis is crucial. In this study, we evaluated whether amide proton transfer-weighted (APTw) imaging was useful to distinguish PCNSL from glioblastoma, IDH-wildtype. The mean APTw signal value did not significantly differ between them; however, the percentile values from the 1st percentile to the 20th percentile APTw signals and the width(1–100) APTw signals between the two diseases were significantly different. The area under the curve, sensitivity, and specificity were 0.796, 64.3%, and 88.9%, respectively, using the width(1–100) APTw signal values. APTw imaging was useful to differentiate between PCNSL and glioblastoma, IDH-wildtype. Performing APTw imaging is recommended in cases in which PCNSL is one of the differential diagnoses. ABSTRACT: Distinguishing primary central nervous system lymphoma (PCNSL) from glioblastoma, isocitrate dehydrogenase (IDH)-wildtype is sometimes hard. Because the role of operation on them varies, accurate preoperative diagnosis is crucial. In this study, we evaluated whether a specific kind of chemical exchange saturation transfer imaging, i.e., amide proton transfer-weighted (APTw) imaging, was useful to distinguish PCNSL from glioblastoma, IDH-wildtype. A total of 14 PCNSL and 27 glioblastoma, IDH-wildtype cases were evaluated. There was no significant difference in the mean APTw signal values between the two groups. However, the percentile values from the 1st percentile to the 20th percentile APTw signals and the width(1–100) APTw signals significantly differed. The highest area under the curve was 0.796, which was obtained from the width(1–100) APTw signal values. The sensitivity and specificity values were 64.3% and 88.9%, respectively. APTw imaging was useful to distinguish PCNSL from glioblastoma, IDH-wildtype. To avoid unnecessary aggressive surgical resection, APTw imaging is recommended for cases in which PCNSL is one of the differential diagnoses. MDPI 2023-02-02 /pmc/articles/PMC9913574/ /pubmed/36765909 http://dx.doi.org/10.3390/cancers15030952 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ohba, Shigeo Murayama, Kazuhiro Teranishi, Takao Kumon, Masanobu Nakae, Shunsuke Yui, Masao Yamamoto, Kaori Yamada, Seiji Abe, Masato Hasegawa, Mitsuhiro Hirose, Yuichi Three-Dimensional Amide Proton Transfer-Weighted Imaging for Differentiating between Glioblastoma, IDH-Wildtype and Primary Central Nervous System Lymphoma |
title | Three-Dimensional Amide Proton Transfer-Weighted Imaging for Differentiating between Glioblastoma, IDH-Wildtype and Primary Central Nervous System Lymphoma |
title_full | Three-Dimensional Amide Proton Transfer-Weighted Imaging for Differentiating between Glioblastoma, IDH-Wildtype and Primary Central Nervous System Lymphoma |
title_fullStr | Three-Dimensional Amide Proton Transfer-Weighted Imaging for Differentiating between Glioblastoma, IDH-Wildtype and Primary Central Nervous System Lymphoma |
title_full_unstemmed | Three-Dimensional Amide Proton Transfer-Weighted Imaging for Differentiating between Glioblastoma, IDH-Wildtype and Primary Central Nervous System Lymphoma |
title_short | Three-Dimensional Amide Proton Transfer-Weighted Imaging for Differentiating between Glioblastoma, IDH-Wildtype and Primary Central Nervous System Lymphoma |
title_sort | three-dimensional amide proton transfer-weighted imaging for differentiating between glioblastoma, idh-wildtype and primary central nervous system lymphoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913574/ https://www.ncbi.nlm.nih.gov/pubmed/36765909 http://dx.doi.org/10.3390/cancers15030952 |
work_keys_str_mv | AT ohbashigeo threedimensionalamideprotontransferweightedimagingfordifferentiatingbetweenglioblastomaidhwildtypeandprimarycentralnervoussystemlymphoma AT murayamakazuhiro threedimensionalamideprotontransferweightedimagingfordifferentiatingbetweenglioblastomaidhwildtypeandprimarycentralnervoussystemlymphoma AT teranishitakao threedimensionalamideprotontransferweightedimagingfordifferentiatingbetweenglioblastomaidhwildtypeandprimarycentralnervoussystemlymphoma AT kumonmasanobu threedimensionalamideprotontransferweightedimagingfordifferentiatingbetweenglioblastomaidhwildtypeandprimarycentralnervoussystemlymphoma AT nakaeshunsuke threedimensionalamideprotontransferweightedimagingfordifferentiatingbetweenglioblastomaidhwildtypeandprimarycentralnervoussystemlymphoma AT yuimasao threedimensionalamideprotontransferweightedimagingfordifferentiatingbetweenglioblastomaidhwildtypeandprimarycentralnervoussystemlymphoma AT yamamotokaori threedimensionalamideprotontransferweightedimagingfordifferentiatingbetweenglioblastomaidhwildtypeandprimarycentralnervoussystemlymphoma AT yamadaseiji threedimensionalamideprotontransferweightedimagingfordifferentiatingbetweenglioblastomaidhwildtypeandprimarycentralnervoussystemlymphoma AT abemasato threedimensionalamideprotontransferweightedimagingfordifferentiatingbetweenglioblastomaidhwildtypeandprimarycentralnervoussystemlymphoma AT hasegawamitsuhiro threedimensionalamideprotontransferweightedimagingfordifferentiatingbetweenglioblastomaidhwildtypeandprimarycentralnervoussystemlymphoma AT hiroseyuichi threedimensionalamideprotontransferweightedimagingfordifferentiatingbetweenglioblastomaidhwildtypeandprimarycentralnervoussystemlymphoma |